Thursday, January 25, 2024 1:46:45 PM
Recent AKBA News
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 10/01/2024 08:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/13/2024 04:15:10 AM
- Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis • PR Newswire (US) • 09/05/2024 12:00:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 09/03/2024 08:16:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/03/2024 08:07:59 PM
- Akebia Therapeutics to Present at Upcoming Investor Conferences • PR Newswire (US) • 08/26/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 11:52:02 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:06:18 AM
- Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights • PR Newswire (US) • 08/08/2024 11:00:00 AM
- Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights • PR Newswire (US) • 08/02/2024 12:00:00 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 08/01/2024 08:05:00 PM
- Akebia Therapeutics to Present at Upcoming Investor Conferences • PR Newswire (US) • 07/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 10:05:02 AM
- Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets • PR Newswire (US) • 07/11/2024 10:00:00 AM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 07/01/2024 08:05:00 PM
- Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference • PR Newswire (US) • 06/27/2024 12:18:00 PM
- Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer • PR Newswire (US) • 06/24/2024 12:58:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:20:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:20:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 08:19:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:09:32 PM
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 06/03/2024 08:05:00 PM
- Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference • PR Newswire (US) • 05/23/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 08:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 08:04:58 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM